Navigation Links
Sinovac Receives Healive(R) and Bilive(R) Purchase Orders from Provincial CDCs for Earthquake Disaster Areas
Date:6/16/2008

BEIJING, June 16 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced that the Shanxi Center for Disease Control and Prevention (CDC) ordered 257,100 doses of Healive(R), the inactivated hepatitis A vaccine manufactured by Sinovac. On the same day, the Gansu CDC ordered 47,000 doses of Bilive(R), a combined hepatitis A and hepatitis B vaccine manufactured by Sinovac. The vaccine purchased by the local CDCs will be utilized to inoculate children in the disaster zones following the May 12th earthquake to prevent the infectious disease. Concurrently, Sinovac donated an additional 8,000 doses of Healive(R) to affected areas in the Shanxi Province. Sinovac's clinical experts were dispatched to the inoculation area to assist the local CDCs with immunization.

Mr. Weidong Yin, Chairman, CEO and President of Sinovac, commented, "The delivery of additional vaccines to the earthquake area reflects our consistent commitment to contribute to improving human health across China. Sinovac's highly efficient manufacturing operations enable us to play a significant role in supplying vaccines for the prevention of infectious diseases during emergency situations. Our established post sales service programs allow for the timely distribution of vaccines to the local CDC doctors in earthquake disaster areas."

As previously announced, the Beijing municipal government purchased on June 11 80,000 doses of Bilive(R), the combined inactivated hepatitis A and B vaccine manufactured by Sinovac, and the vaccines were delivered to disaster area in Gansu Province. Sinovac donated on May 19 to the earthquake disaster area 50,000 doses of Healive(R), of which 10,000 doses were sent to the Gansu province. On May 22, the Ministry of Health purchased approximately RMB 20 million of Healive(R).

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), Anflu(R) (influenza) and Panflu(TM) (H5N1). Sinovac is currently developing Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine. Additional information about Sinovac is available on its website, http://www.sinovac.com . To be added to our distribution list, please email: info@sinovac.com.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For more information, please contact:

Helen G. Yang

Sinovac Biotech Ltd.

Tel: +86-10-8289-0088 x871

Fax: +86-10-6296-6910

Email: info@sinovac.com

Investors/Media:

Stephanie Carrington / Janine McCargo

The Ruth Group

Tel: +1-646-536-7017/7033

Email: scarrington@theruthgroup.com / jmccargo@theruthgroup.com


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovac Receives RMB 20 Million Purchase Order for Healive from Chinas Ministry of Health to Vaccinate Earthquake Victims
2. Sinovac to Present at the Brean Murray, Carret & Co. All-Cap All-China Conference and the Roth China Discovery Tour 2008
3. Sinovac Biotech Holds Annual General Meeting
4. Sinovac Reports Fourth Quarter and Full Year 2007 Financial Results
5. Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2007 Financial Results
6. Sinovac Announces Adjournment of Annual General Meeting
7. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
8. Sinovac Closes $9.75 Million Private Placement
9. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
10. Sinovac Requests Extension for Annual Shareholders Meeting
11. Sinovac Announces Postponement of Annual General Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... October 10, 2017 , ... ... company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that ... Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO of ... Club. The event entitled “Stem Cells and Their Regenerative Powers,” was ... Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., ...
(Date:10/10/2017)... CRUZ, Calif. , Oct. 10, 2017 ... grant from the NIH to develop RealSeq®-SC (Single Cell), ... kit for profiling small RNAs (including microRNAs) from single ... Analysis Program highlights the need to accelerate development of ... "New techniques for measuring ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program ... honoring scientists who have made outstanding contributions to analytical chemistry and ... 2018, the world’s leading conference and exposition for laboratory science, which will be ...
Breaking Biology Technology:
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
(Date:3/27/2017)... N.Y. , March 27, 2017  Catholic ... Information and Management Systems Society (HIMSS) Analytics for ... EMR Adoption Model sm . In addition, CHS ... of U.S. hospitals using an electronic medical record ... for its high level of EMR usage in ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
Breaking Biology News(10 mins):